Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27889507 | 0.98 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL27889589 | 0.98 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL10126309 | 0.98 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL250349 | 0.91 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL30127786 | 0.91 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL9664897 | 0.89 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL5713368 | 0.85 | TLR8 (0.51) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4887109 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29611102 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL14888955 | 0.83 | TLR8 (0.53) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005110950-A1 | SYNTHESIS OF UNSYMMETRIC ANTHRACENE COMPOUNDS | EASTMAN KODAK COMPANY (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050245752-A1 | Synthesis of unsymmetric anthracene compounds | EASTMAN KODAK COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245752-A1 | Synthesis of unsymmetric anthracene compounds | PFAS, ACSL3, AFF2 | KDM4E 2314/4885ALDH1A1 2409/4885HPGD 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.